Frontotemporal dementia

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, April 1, 2024
Lewy body, Research, GBA, Administration, Plasma, Conference, MRI, DLB, GFAP, Basal forebrain, Patient, Journal, Chairperson, Sale, TID, Manuscript, Public expenditure, Biomarker, Glial fibrillary acidic protein, MD, University College London, Atrophy, Publication, Frontotemporal dementia, Alpha-synuclein, NIA, Research and development, Vertex Pharmaceuticals, Axonal transport, Dementia, CRVO

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.

Cerevance Announces Presentation at Alzheimer’s Research UK Conference

Retrieved on: 
Wednesday, March 13, 2024
Brain, Conference, ALS, Central nervous system, CNS, Microglia, NLRP3, KCNK13, Frontotemporal dementia, Poster, Therapy, Neuroinflammation, FTD

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster at the upcoming Alzheimer’s Research UK Conference, taking place in Liverpool, United Kingdom, March 20-21, 2024.

Key Points: 
  • BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster at the upcoming Alzheimer’s Research UK Conference, taking place in Liverpool, United Kingdom, March 20-21, 2024.
  • Overview: Cerevance’s NETSseq platform enables the identification of novel targets, such as KCNK13 (THIK1), from specific cell types in the human brain.
  • Following the discovery of KCNK13, Cerevance has developed CVN293, a novel compound that selectively inhibits KCNK13 and reduces the release of IL-1β from microglia dependent on NLRP3.
  • CVN293 shows promise in potentially addressing CNS conditions characterized by neuroinflammation, such as frontotemporal dementia (FTD), Amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease.

EverythingALS Launches the Vision 2030 AI Hub: Charting the Path to an ALS Cure and Advancing Neurodegenerative Disease Research

Retrieved on: 
Tuesday, March 12, 2024
Research, Neurology, Harvard Medical School, Synthetic media, Machine learning, Government, Regeneration, Prevalence, Massachusetts General Hospital, Science, Environment, MIT, Data science, SAN, Knowledge, Biomarker, History, Hope, Doctor of Philosophy, LLM, Vision 2030, Hub, Ecosystem, Drug development, Navar, Frontotemporal dementia, Artificial intelligence, Generative, Mass, Medicine, Medical device

The Vision 2030 AI Hub will have a laser focus on "repair and regeneration," aiming to distinguish the organization in the ALS research landscape.

Key Points: 
  • The Vision 2030 AI Hub will have a laser focus on "repair and regeneration," aiming to distinguish the organization in the ALS research landscape.
  • The Vision 2030 AI Hub epitomizes this momentous convergence—where the cumulative advances in ALS research and technology coalesce, heralding a new epoch of hope and discovery.
  • The Vision 2030 AI Hub motivates giving and fundraising, showcasing an innovative operating model that emphasizes urgency in tackling ALS and other disorders.
  • For more information about EverythingALS, Vision 2030, and the AI Hub visit http://www.v2030.org or email us at [email protected] .

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Research, Pharmacology, LD, Survival, Serum, ALS, Science, PD, Houston Methodist Hospital, Patient, Regulatory affairs, Granulocyte-macrophage colony-stimulating factor, FD, GM-CSF, Nebraska Medicine, COYA, University, IPO, Senior, Society, IND, Commerce, Viral disease, Therapy, Frontotemporal dementia, FDA, FTD, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.
  • COYA 302 is Coya’s combination of its proprietary LD IL-2 formulation with the immunomodulatory drug CTLA4-Ig.
  • “We believe that we have under-promised and over-delivered in executing on numerous deliverables in 2023 that have brought value to Coya,” commented Howard Berman, Ph.D., Chief Executive Officer of Coya.
  • Net loss was $8.0 million for the year ended December 31, 2023, compared to net loss of $12.2 million for the year ended December 31, 2022.

Unlearn’s TwinRCT Solution Update Enhances Phase 2 Trial Decision-Making Power

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Clinical Trials, Clutch (eggs), Frontotemporal dementia, Disease, Stroke, Clinical trial, Parkinson's disease, AI, ALS, Medicine, Pharmaceutical industry

Unlearn ®, a company at the forefront of AI in medicine, today announced the newest version of its TwinRCT™ solution, TwinRCT 3.0.

Key Points: 
  • Unlearn ®, a company at the forefront of AI in medicine, today announced the newest version of its TwinRCT™ solution, TwinRCT 3.0.
  • TwinRCTs are randomized clinical trials that use digital twins of trial participants—comprehensive forecasts of individual clinical outcomes—to optimize clinical trials.
  • Unlearn’s updated TwinRCT can now incorporate additional previous clinical trial data to provide an even more robust framework for Phase 2 trial evaluations, which represent a crucial stage in the drug development process.
  • The results of a case study reanalyzing a completed Alzheimer’s Disease study demonstrate that a traditional trial would require 23% more trial participants to achieve the same power as Unlearn’s updated TwinRCT.

PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions

Retrieved on: 
Tuesday, March 12, 2024
Gene, Methylation, FTD, FMR1, ALS, Associate, Myotonic dystrophy, Abraxis BioScience, Huntington's disease, DNA, Apple IIe, Ataxia, Laboratory, University College London, Frontotemporal dementia, DSM-IV codes, Mosaic, High fidelity, Instability

MENLO PARK, Calif., March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions. The new long-read workflow can minimize iterative analysis using legacy technology, and reduce the time needed to identify disease-causing variants and associated methylation signatures.

Key Points: 
  • "This product uses a differentiated method to do targeted long-read sequencing of DNA in its pure state.
  • Continuing the commitment to deliver comprehensive solutions, PacBio has prioritized delivering end-to-end workflows with their latest products.
  • The PureTarget Repeat Expansion Panel workflow utilizes the recently announced Nanobind PanDNA kit , ensuring robust results optimized for Revio and Sequel IIe users.
  • Customers can multiplex up to 48 samples on the PacBio Revio sequencing system and 24 samples on the PacBio Sequel IIe sequencing system.

QurAlis to Present at the Stifel 2024 CNS Days

Retrieved on: 
Tuesday, March 12, 2024
Frontotemporal dementia, ALS, FTD

CAMBRIDGE, Mass., March 12, 2024 /PRNewswire/ -- QurAlis Corporation , a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that will alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, today announced that Kasper Roet, Ph.D., chief executive officer and co-founder, will present a corporate overview at the Stifel 2024 CNS Days being held virtually, March 19-20, 2024.

Key Points: 
  • CAMBRIDGE, Mass., March 12, 2024 /PRNewswire/ -- QurAlis Corporation , a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that will alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, today announced that Kasper Roet, Ph.D., chief executive officer and co-founder, will present a corporate overview at the Stifel 2024 CNS Days being held virtually, March 19-20, 2024.
  • Dr. Roet's presentation will take place on Wednesday, March 20, 2024 at 1:30 PM ET.
  • A live webcast of Dr. Roet's presentation may be accessed via https://bit.ly/3wyluNp .

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Monday, March 4, 2024
GRN, Granulin, Interim management, Cohort, Senior, ALS, Alzheimer's disease, GM1, PASG, Research and development, Frontotemporal dementia, FTD, Interim, Safety, Immunosuppression, Administration, Patient, Clinical trial, CSF, Krabbe disease, Pharmaceutical industry

"In 2023, we achieved a significant milestone by announcing encouraging data from three patients in Cohort 1 of our FTD-GRN program.

Key Points: 
  • "In 2023, we achieved a significant milestone by announcing encouraging data from three patients in Cohort 1 of our FTD-GRN program.
  • We eagerly anticipate a catalyst-rich 2024, supported by our robust balance sheet, bringing us closer to improving patient outcomes across neurodegenerative diseases."
  • Additionally, Dose 1 of PBFT02 continued to be generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression.
  • Cash Position: Cash, cash equivalents and marketable securities were $114.3 million as of December 31, 2023, as compared to $189.6 million as of December 31, 2022.

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024
PD, GSK, Arnon Rosenthal, Investment, Interest, ARIA, AbbVie, Webcast, Plasma, PET, MRI, Central nervous system, Traffic barrier, GPNMB, Cerebrospinal fluid, Breakthrough therapy, ALEC, Frontotemporal dementia, FTD, DSM-IV codes, European Medicines Agency, Food and Drug Administration, Canadian International Council, Brain, SAN, Total, LTE, Amyloid-related imaging abnormalities, Alector, ALS, AAIC, PROGRESS, ABC, Manuscript, Conference, Safety, Biomarker, Patent, CSF, Mutation, IND, Microglia, European Patent Convention, Insurance, PIN, FDA, Food, Risk, TREM2, Dementia, Disease, Pharmaceutical industry

Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
  • In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
  • Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference

Retrieved on: 
Wednesday, March 6, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Central nervous system, Investigational New Drug, Houston Methodist Hospital, Chemokine, Frontotemporal dementia, Messenger, FDA, COYA, Conference, FTD, Therapy, Pathology, Patient, Poster, Role, IND, Pharmaceutical industry

The poster presentation was shared for the first time today at the AD/PD 2024 Conference in Lisbon, Portugal and can be found here .

Key Points: 
  • The poster presentation was shared for the first time today at the AD/PD 2024 Conference in Lisbon, Portugal and can be found here .
  • We intend to file an Investigational New Drug (IND) application with the FDA for COYA 302 in FTD later this year and initiate a Ph.
  • 2 trial in FTD patients shortly thereafter,” stated Fred Grossman, Chief Medical Officer at Coya Therapeutics.
  • In addition, several inflammation transcripts in monocyte genes known to be involved in neuroinflammatory signaling pathways were dysregulated in FTD, compared to controls.